A. Seyed-Mozaffari

发表

Identification and quantification of the indole alkaloid ibogaine in biological samples by gas chromatography-mass spectrometry.

S. D. Glick, S. Archer, L. Hough, 1995, Biochemical pharmacology.

Preparation and antischistosomal and antitumor activity of hycanthone and some of its congeners. Evidence for the mode of action of hycanthone.

D. Cioli, S. Archer, L. Pica-Mattoccia, 1988, Journal of medicinal chemistry.

14 beta-(Bromoacetamido)morphine irreversibly labels mu opioid receptors in rat brain membranes.

S. Archer, A. Seyed-Mozaffari, J. Bidlack, 1989, Biochemistry.

Fluorescent staining of κ opioid receptors using naltrexamine derivatives and phycoerythrin

J. Bidlack, D. M. Lawrence, S. Archer, 1997 .

Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice.

J. Bidlack, Q. Jiang, S. Archer, 1993, European journal of pharmacology.

Photoaffinity ligands for the mu opioid receptor.

E. J. Simon, J. Hiller, S. Archer, 1993, Life sciences.

Hybromet: a ligand for purifying opioid receptors.

E. J. Simon, R. Zukin, T. Gioannini, 1985, Journal of medicinal chemistry.

Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism

Q. Jiang, A. Sebastian, S. Archer, 1994, Regulatory Peptides.

Affinity labeling of mu opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone.

S. Archer, A. Seyed-Mozaffari, J. Bidlack, 1990, Molecular pharmacology.

Synthesis and characterization of 7-nitrobenzo-2-oxa-1,3-diazole (NBD)-labeled fluorescent opioids.

P. Emmerson, F. Medzihradsky, S. Archer, 1992, Biochemical pharmacology.

Opioid ligands related to tifluadom

E. J. Simon, T. Gioannini, S. Archer, 1989 .

Affinity labeling of the mu opioid receptor in bovine striatal membranes with [3H]-14 beta-(bromoacetamido)-7,8-dihydromorphine.

R. Subbramanian, S. Archer, A. Seyed-Mozaffari, 1993, Biochemistry.

Mode of action of the schistosomicide hycanthone: site of DNA alkylation.

W. El-hamouly, D. Cioli, S. Archer, 1990, Molecular and biochemical parasitology (Print).

N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.

J. Bidlack, S. Archer, A. Seyed-Mozaffari, 1996, The Journal of pharmacology and experimental therapeutics.

N-Methyl and N-cyclopropylmethyl-14α,14′β-[dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydro-5β-methyl-morphinone) MET-TAMO and N-CPM-MET-TAMO: Synthesis and opioid binding properties

J. Bidlack, A. Sebastian, S. Archer, 1995 .

14 alpha,14' beta-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14 alpha,14' beta-[dithiobis[(2-oxo-2,1- ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties.

J. Bidlack, Q. Jiang, S. Archer, 1994, Journal of medicinal chemistry.

Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO).

J. Bidlack, Q. Jiang, S. Archer, 1993, The Journal of pharmacology and experimental therapeutics.

Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).

J. Bidlack, Q. Jiang, S. Archer, 1992, The Journal of pharmacology and experimental therapeutics.

14β-Thioglycolamido-7,8-dihydromorphinone, a μ-Selective Irreversible Ligand.

J. Bidlack, A. Seyed-Mozaffari, S. Archer, 1991 .

14 beta-(2-bromoacetamido)morphine and 14 beta-(2-bromoacetamido)morphinone.

J. Bidlack, L. Abood, S. Archer, 1983, Journal of medicinal chemistry.